Medical Cannabis is an exciting new field of medicine.
It promises real hope for people with conditions that don’t respond to other drugs, as well as for the horticultural industry.

Medical Cannabis is already well known as a medicine for pain relief. It’s now also being prescribed to support people in sleeping and other conditions such as anxiety and pain. And we’re still discovering other potential uses.

Eqalis was established in 2019 to bring together everything needed to grow, manufacture and distribute high quality medicinal cannabis to those who need it.

We’re based in the Bay of Plenty, New Zealand’s horticultural heartland and home to some of the country’s most innovative growers. We’re led by an amazing team of health professionals committed to making effective new treatments available.
Alongside them are some of the best business minds you’ll ever find, all working to see that our work benefits everyone: growers, shareholders, iwi, and, above all, those who use our products.

With evidence-based science at the heart of all we do, we’re at the forefront of New Zealand medical Cannabis.

What is Eqalis about?

It’s about balance

Cannabis has a powerful ability to bring the body back to its natural state of equilibrium. That’s the state where everything is functioning as it should, and all the parts are working smoothly together.
Equilibrium is like balance, but active.

We’ve drawn on Cannabis’s beneficial elements to produce medical Cannabis that works throughout the body to support homeostasis; the total stability of the body’s internal systems.

And quality of life

Measuring how effective a medicine is important. We use QALY (short for Quality Adjusted Life Year), a globally recognised system that determines a medicine’s value based on the quality of life it provides. This is different from many other measures that focus on specific, limited outcomes, that don’t take into account what life is like for the person after they have taken the medicine.

QALY is central to what we do – growing our finest quality ingredients under the strictest of conditions, so we can help build a healthier and happier New Zealand.

The Statera icon, which we’ve chosen as our symbol, represents balance, wholeness, symmetry, targeted relief, and continuous development. There’s also the suggestion of a flower within the icon, a happy allusion to our horticultural heritage.

Find your equilibrium

Exploring Medicinal Cannabis

Last year the law changed to make medicinal cannabis available in New Zealand. This increases treatment options and, for some people, may make a huge difference to their quality of life.

Cannabis medicines are just like any other prescription medicine that your doctor might prescribe. They are prescription only and are dispensed by pharmacies.

Cannabis medicine is recognised as a treatment option for pain relief and in helping people with sleep disorders, pain relief and anxiety. Its full range of possible uses is still being explored and it’s likely that further uses will be discovered.

Like other medicines, cannabis medicines can be both beneficial and also cause unwanted side effects. Because your doctor knows your medical history and what other medicines you are taking, he or she can advise whether cannabis medicine is a good and safe option for you.

Doctors Are Learning Too

All new medicines take time before becoming fully understood by the people who might prescribe them. Cannabis is no different.

You can help your doctor by doing your own research. Share with them any good, evidence-based articles you find about the effective use of cannabis for your condition. Let them know medicines you’ve tried already and with what results. This will help them assess if medicinal cannabis could support you or the condition you’re dealing with.

If your GP is not comfortable making a judgement on prescribing medicinal cannabis, ask if they can refer you to a doctor with expertise in this area. Specialist cannabis clinics in New Zealand like: RestoreMe Clinic

How Cannabinoids Work

It’s only in the last 30 years or so that we’ve begun to understand why cannabis has such an effect on the human body.

That’s when we discovered the human endocannabinoid system, a network of receptors throughout our bodies (including all the major organs including the brain, the central nervous system, and the immune system). Receptors are like locks that open when a key (in this case a cannabinoid) is inserted into them. When a receptor is “opened”, it produces a physiological response such as the release of adrenalin or dopamine.

Your body already produces cannabinoids which help regulate many of the physiological processes needed for life. Cannabis offers a range of other cannabinoids that the body doesn’t produce, and each one may produce – or inhibit – a particular physiological response.

The better we understand cannabis and the compounds within it, the better we understand its potential for treating various health conditions and contributing to a better quality of life.

Research so far shows that cannabis-based medicines may be effective in treating chronic pain, epilepsy, sleep disorders and some gastrointestinal disorders. It also shows promise in other conditions, but it’s also too early to make bold claims one way or the other.

‘CB1 Receptors are abundant in the central nervous system particularly in the cortex, basal ganglia, hippocampus and cerebellum’(2) however are sparse within the brainstem(3).
• Highly concentrated in brain/CNS, involved in executive function.

‘CB2 Receptors are abundant throughout the body located in organs, however are present in much lower levels compared to CB1 receptors in the brain(2).
• Emphasis on Immune System

(1) Sulak, D., 2015, The Endocannabinoid System,, viewed 2 April 2016 < endocannabinoid-system/>
(2) Lu, H.C, Mackie, K.,2016, An Introduction to the Endogenous Cannabinoid System, Biological Psychiatry, Vol. 79, p.517.
(3) Backes, M., 2014, Cannabis Pharmacy: The Practical Guide to medical Marijuana, Black Dog & Leventhal Publishers, New York, P.41.
(4) Baker, D., Pryce, G., Davies, W.L., Hiley, C.R., 2006 In silico patent searching reveals a new cannabinoid receptor, Trends in Pharmacological Sciences, Vol.27, No.1, p.p. 1-4.
(5) Fride, E., Foox, A., Rosenburg, E., Faigenbolm, M., Cohen, V., Barda, L., Blau, H., Mechoulam, R., 2003, Milk intake and survival in newborn cannibinoid CB1 receptor knockout mice: evidence for a “CB3” receptor, European Journal of Pharmacology, Vol.461, No1, p.p.27-34.

Epilepsy Action Australia ©2017

Contact Us

Contact the Eqalis team to learn more about this groundbreaking new era of medicine.